by Katie Oakley | Sep 24, 2014
FDA has been granted approval to move forward with a May 2014 study proposal to analyze the effects of distractions in drug advertisements. In the study announcement FDA explains, “We hypothesize that distracting audio and visuals during the major statement will...
by Katie Oakley | Sep 17, 2014
Pearl Pathways is pleased to announce that our own Gretchen Bowker will be speaking at the 2014 RAPS Preconference Workshop entitled Regulatory Strategy Forum for Biologics. She will be presenting at the 11am session on conducting clinical trials, which will cover the...
by Katie Oakley | Sep 12, 2014
Pearl Pathways’ own President and CEO, Diana Caldwell will be featured at the 2014 Site Solutions Summit as a moderator for the Crowdsolving topic entitled Tweet, Post, Like, Engage In Social Media For Results. In aligmnent with the structure of Crowdsolving sessions,...
by Katie Oakley | Sep 10, 2014
Similar to the pharmaceutical “Orange Book,” FDA has recently published the first edition of the “Purple Book” of biological products, which is intended to provide the regulatory community with information on the interchangeability of biosimilars. The book is divided...
by Katie Oakley | Sep 8, 2014
In addition to sponsoring the 2014-2015 Indiana Life Sciences Collaboration Conference Series, Pearl Pathways is proud to announce that both of our co-founders, Diana Caldwell and Gretchen Bowker, will be serving as moderators for this year’s first conference entitled...